Reduction of draining tunnels sustained to three years: Of patients who had at least one draining tunnel at baseline, 48.2% had none at one year, and 62.9% at three years* – indicating sustained ...

For years, HS was treated like an infection. Experts explain what's changed-and how today's treatments target the disease at ...

Over half of patients had no draining tunnels (DTs) at two years: In 425 hidradenitis suppurativa (HS) patients with ≥1 DTs at baseline, 55.7% (195/350) had no DTs at two years of treatment. ≠ DTs are ...

ATLANTA, March 8, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies examining ...

Jeff Stark, MD, vice president and head of immunology, UCB, discusses findings on improved pain management in patients with moderate to severe hidradenitis suppurativa (HS). Treatment with bimekizumab ...

What looks like a skin issue is actually something deeper. Experts explain the inflammatory cycle driving HS-and why it keeps ...

Patients with hidradenitis suppurativa (HS) need wound care not only after surgery, to address HS scarring and tunneling from sinus tracts, but they also need ongoing wound care for lesions that might ...

Learning to manage hidradenitis suppurativa can be an ongoing process. The chronic skin condition causes painful lumps under the skin, especially in the armpits, groin, and under the breasts, ...

Brussels (Belgium), March 7, 2025 – 14:00 (CET) – UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX ® (bimekizumab-bkzx) in moderate to ...

Hidradenitis suppurativa (HS) is a chronic, painful, and debilitating inflammatory skin disease that is associated with systemic manifestations.2 5,26 The main symptoms are nodules, abscesses, and pus ...